FDA's Push for AI-Based Trial Alternatives and Organoids in Animal Testing Phaseout
Wednesday, 7 May 2025, 11:56
FDA's Announcement on Animal Testing Phaseout
The FDA recently revealed its plans to phase out animal testing in drug development, promoting the adoption of alternatives such as AI-based trial methodologies and organoids. This change is significant as it emphasizes the commitment to ethical research practices while fostering innovation in biomedical research.
Importance of NAMs
- Ethical considerations surrounding animal testing.
- Potential of AI and organoids to provide reliable data.
- Exploring new approach methodologies (NAMs) to improve testing standards.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.